Toxic Shock Syndrome and Persistent Immune Activation in an HIVPositive Patient

Author(s): Michal Holub, Simona Arientová, David Jilich, Alzbeta Davidová, Ondrej Beran, Hanus Rozsypal

Journal Name: Current HIV Research

Volume 11 , Issue 4 , 2013

Become EABM
Become Reviewer


The case of an HIV-positive treatment-naive male with toxic shock syndrome (TSS) is presented herein. The course of TSS was favorable; however, the patient had extremely high plasma levels of MCP-1 and CD38 and HLA-DR expression on CD8+ T cells during the acute illness. Furthermore, the numbers of CD8+ T cells were reduced and CD4+ T cells remained stable during acute illness in comparison to baseline values. MCP-1 and HLA-DR gradually decreased, but they were still elevated after a month, whereas the number of circulating CD8+ T cells increased more than fivefold. CD38 expression remained stable during this period. A further decrease in CD38, HLA-DR and MCP-1 was noted five months after the initiation of antiretroviral therapy.

Keywords: Combined antiretroviral therapy, CD38, HIV infection, HLA-DR, MCP-1, toxic shock syndrome.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 22 September, 2013
Page: [321 - 325]
Pages: 5
DOI: 10.2174/1570162X113119990045
Price: $65

Article Metrics

PDF: 7